• Pharma and Biotech Daily: AbbVie Criticizes Trump's Drug Pricing Proposal, Gilead Pushes Forward, and SpringWorks Merger with Merck KGaA

  • Apr 28 2025
  • Duración: 1 m
  • Podcast

Pharma and Biotech Daily: AbbVie Criticizes Trump's Drug Pricing Proposal, Gilead Pushes Forward, and SpringWorks Merger with Merck KGaA

Escúchala gratis

Ver detalles del espectáculo

  • Resumen

  • Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.AbbVie, a pharmaceutical company, has criticized President Trump's drug pricing proposal despite reporting strong earnings this quarter. The company is facing challenges with declining sales of its drug Humira and a struggling aesthetics business. Meanwhile, Gilead is moving forward with the launch of its HIV drug despite macro pressures in the industry. FDA Commissioner Marty Makary's recent statements have been fact-checked, with some contradictions emerging.In other news, SpringWorks is potentially being bought out by Merck KGaA for $3.5 billion. Wacker Biotech is offering services for advanced therapies. Stay tuned for more updates on these developments in the pharmaceutical and biotech sectors.
    Más Menos
Más Menos
adbl_web_global_use_to_activate_webcro805_stickypopup

Lo que los oyentes dicen sobre Pharma and Biotech Daily: AbbVie Criticizes Trump's Drug Pricing Proposal, Gilead Pushes Forward, and SpringWorks Merger with Merck KGaA

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.

Reseñas de Audible.com

Opiniones de Amazon
No hay comentarios disponibles